NEW HAVEN, Conn., Oct. 1 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION - News) has been awarded a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID). The grant, entitled "Determination of Triapine® Antiviral Activity," supports preclinical studies intended to assess the activity of Triapine® in combination with various nucleoside analogues against human immunodeficiency (HIV), herpes simplex (HSV), and hepatitis B (HBV) viruses. The studies will be conducted in collaboration with Dr. Yung-Chi Cheng of Yale University School of Medicine.
